PF PRISM CV Company Profile

✉ Email this page to a colleague

PF PRISM CV has sixteen approved drugs.

There are twenty-nine US patents protecting PF PRISM CV drugs.

There are six hundred and thirteen patent family members on PF PRISM CV drugs in sixty-six countries and seventy-two supplementary protection certificates in eighteen countries.

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pf Prism Cv	CHANTIX	varenicline tartrate	TABLET;ORAL	021928-001	May 10, 2006		DISCN	Yes	No		⤷ Sign Up				⤷ Sign Up
Pf Prism Cv	XALKORI	crizotinib	CAPSULE;ORAL	202570-001	Aug 26, 2011		RX	Yes	No	7,230,098	⤷ Sign Up		Y		⤷ Sign Up
Pf Prism Cv	BOSULIF	bosutinib monohydrate	CAPSULE;ORAL	217729-001	Sep 26, 2023		RX	Yes	No		⤷ Sign Up				⤷ Sign Up
Pf Prism Cv	INLYTA	axitinib	TABLET;ORAL	202324-002	Jan 27, 2012		RX	Yes	Yes	10,570,202	⤷ Sign Up				⤷ Sign Up
Pf Prism Cv	TYGACIL	tigecycline	POWDER;INTRAVENOUS	021821-001	Jun 15, 2005	AP	RX	Yes	Yes	8,372,995	⤷ Sign Up	Y			⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pf Prism Cv	VFEND	voriconazole	FOR SUSPENSION;ORAL	021630-001	Dec 19, 2003	5,773,443	⤷ Sign Up
Pf Prism Cv	RAPAMUNE	sirolimus	TABLET;ORAL	021110-002	Aug 22, 2002	5,308,847*PED	⤷ Sign Up
Pf Prism Cv	TYGACIL	tigecycline	POWDER;INTRAVENOUS	021821-001	Jun 15, 2005	5,494,903	⤷ Sign Up
Pf Prism Cv	TORISEL	temsirolimus	SOLUTION;INTRAVENOUS	022088-001	May 30, 2007	5,362,718*PED	⤷ Sign Up
Pf Prism Cv	VFEND	voriconazole	TABLET;ORAL	021266-002	May 24, 2002	5,364,938	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	0.5 mg and 1 mg	➤ Subscribe	2010-05-10
➤ Subscribe	Tablets	5 mg	➤ Subscribe	2016-11-07
➤ Subscribe	Tablets	100mg and 500mg	➤ Subscribe	2016-09-06
➤ Subscribe	For Injection	200 mg/vial	➤ Subscribe	2008-09-12
➤ Subscribe	Oral Suspension	40 mg/mL	➤ Subscribe	2010-10-08
➤ Subscribe	Injection	25 mg/mL, 1.8 mL vial	➤ Subscribe	2011-05-25
➤ Subscribe	Tablets	0.5 mg	➤ Subscribe	2010-08-25
➤ Subscribe	Extended-release Tablets	25 mg	➤ Subscribe	2015-05-08
➤ Subscribe	Tablets	1 mg and 5 mg	➤ Subscribe	2018-02-23
➤ Subscribe	Tablets	400 mg	➤ Subscribe	2018-10-15
➤ Subscribe	Tablets	50 mg and 200 mg	➤ Subscribe	2008-04-14
➤ Subscribe	For Injection	50 mg per vial	➤ Subscribe	2009-06-15
➤ Subscribe	Tablets	1 mg and 2 mg	➤ Subscribe	2009-12-17
➤ Subscribe	Extended-release Tablets	50 mg and 100 mg	➤ Subscribe	2012-02-29

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration
Cyprus	1124391	⤷ Sign Up
South Africa	200804374	⤷ Sign Up
Cyprus	1114504	⤷ Sign Up
World Intellectual Property Organization (WIPO)	2005046693	⤷ Sign Up
Georgia, Republic of	P20104906	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0763039	122008000023	Germany	⤷ Sign Up	PRODUCT NAME: TEMSIROLIMUS ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/07/424/001 20071119
0763039	PA2008009,C0763039	Lithuania	⤷ Sign Up	PRODUCT NAME: TEMSIROLIMUSUM; REGISTRATION NO/DATE: EU/1/07/424/001 20071119
1786785	PA2013005,C1786785	Lithuania	⤷ Sign Up	PRODUCT NAME: CRIZOTINIBUM; REGISTRATION NO/DATE: EU/1/12/793/001 - EU/1/12/793/004, 2 00121023
1786785	1390008-9	Sweden	⤷ Sign Up	PRODUCT NAME: CRIZOTINIB INKLUSIVE ETT FARMACEUTISKT GODTAGBART SALT, SOLVAT ELLER HYDRAT DAERAV; REG. NO/DATE: EU/1/12/793/001 20121023; PERIOD OF VALIDITY (FROM - UNTIL): 2025-08-16 - 2027-10-25
1666481	C201730033	Spain	⤷ Sign Up	PRODUCT NAME: TOFACITINIB Y SALES FARMACEUTICAMENTE ACEPTABLES DEL MISMO, INCLUYENDO LA SAL CITRATO; NATIONAL AUTHORISATION NUMBER: EU/1/17/1178; DATE OF AUTHORISATION: 20170322; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1178; DATE OF FIRST AUTHORISATION IN EEA: 20170322
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.